EcoDrugPlus

40s Ribosomal Protein S20-Like

Ensembl ID : ENSSLDG00000002596
Gene Symbol: LOC111645317
2 Cross references
354 Possible Orthologues:

40s Ribosomal Protein S24-Like

Ensembl ID : ENSSLDG00000025555
Gene Symbol: LOC111670074
3 Cross references
488 Possible Orthologues:

40s Ribosomal Protein S4

Ensembl ID : ENSSLDG00000003261
Gene Symbol: LOC111667127
3 Cross references
494 Possible Orthologues:

5'-Nucleotidase Ecto

Ensembl ID : ENSSLDG00000021780
Gene Symbol: NT5E
4 Cross references
215 Possible Orthologues:

5'-Nucleotidase-Like

Ensembl ID : ENSSLDG00000003971
Gene Symbol: LOC111644776
4 Cross references
180 Possible Orthologues:

5-Hydroxytryptamine Receptor 1a

Ensembl ID : ENSSLDG00000018461
Gene Symbol: HTR1A
2 Cross references
104 Possible Orthologues:

5-Hydroxytryptamine Receptor 1a-Beta

Ensembl ID : ENSSLDG00000015990
Gene Symbol: LOC111669343
3 Cross references
132 Possible Orthologues:

5-Hydroxytryptamine Receptor 1b

Ensembl ID : ENSSLDG00000021754
Gene Symbol: HTR1B
2 Cross references
184 Possible Orthologues:

5-Hydroxytryptamine Receptor 1b

Ensembl ID : ENSSLDG00000004018
Gene Symbol: HTR1B
2 Cross references
183 Possible Orthologues:

5-Hydroxytryptamine Receptor 1e

Ensembl ID : ENSSLDG00000008969
Gene Symbol: HTR1E
4 Cross references
148 Possible Orthologues:

5-Hydroxytryptamine Receptor 1f

Ensembl ID : ENSSLDG00000024089
Gene Symbol: HTR1F
2 Cross references
142 Possible Orthologues:

5-Hydroxytryptamine Receptor 2a

Ensembl ID : ENSSLDG00000011258
Gene Symbol: HTR2A
3 Cross references
209 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).